A Phase I/II Clinical Study of the KL003 Cell Injection in β-Thalassemia Major Participants

Conditions: Transfusion-dependent Beta-Thalassemia Interventions: Drug: KL003 Cell Injection Drug Product Sponsors: Kanglin Biotechnology (Hangzhou) Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials